Trillium Community Health Plan

Onasemnogene abeparvovec (Zolgensma)

Prior Authorization Form/Prescription

PLEASE COMPLETE ALL SECTIONS FOR A TIMELY REVIEW

Date: _____ Date Medication Required: _____
Ship to: ❍ Physician ❍ Patient's Home ❍ Other _____

Patient Information

Last Name:	First Name:	Middle:	DOB: ____/____/_____
Address:	City:	State:	Zip:
Daytime Phone:	Evening Phone:	Sex: ☐ Male ☐ Female	

Insurance Information (*Attach copies of cards*)

Primary Insurance:		Secondary Insurance:	
ID #	Group #	ID #	Group #
City:	State:	City:	State:

Physician Information

Name:	Specialty:	NPI:	
Address:	City:	State:	Zip:
Phone #:	Secure Fax #:	Office Contact:	

Primary Diagnosis

ICD-10 Code: _____

☐ Spinal muscular atrophy (SMA), type _____ ☐ Other: _____

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
Zolgensma (Onasemnogene abeparvovec)				

Clinical Information

***** *Please submit supporting clinical documentation* *****

☐ **INITIAL THERAPY** ☐ **CONTINUATION OF THERAPY;** Therapy start date: _____

1. Did patient have onset of symptoms prior to 6 months of age? ☐ Yes ☐ No
2. Does patient have 1, 2, or 3 copies of the survival motor neuron 2 (SMN2) gene? ☐ 1 ☐ 2 ☐ 3 ☐ No
3. Does genetic testing confirm any of the following? ☐ Yes ***Mark all that apply*** ☐ No
   - ☐ Homozygous deletions of SMN1 gene (e.g., absence of the SMN1 gene)
   - ☐ Homozygous mutation in the SMN1 gene (e.g., biallelic mutations of exon 7)
   - ☐ Compound heterozygous mutation in the SMN1 gene (e.g., deletion of SMN1 exon 7 [allele 1] and mutation of SMN1 [allele 2])
4. Is therapy prescribed by or in consultation with a neurologist? ☐ Yes ☐ No
5. Please document one of the following:
   a. *Baseline* Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorder (CHOP-INTEND) score: _____
   b. *Baseline* Hammersmith Infant Neurological Examination (HINE) motor milestone score: _____
6. Please document ALL of the following:
   a. *Baseline* laboratory tests demonstrating Anti-AAV9 antibody titers ≤ 1:50 as determined by ELISA binding immunoassay: _____
   b. *Baseline* liver function test:_____, platelet counts:_____, troponin-I:_____
7. Does patient have advanced SMA (e.g., complete paralysis of limbs, permanent ventilator dependence, tracheostomy, non-invasive ventilation beyond the use for sleep)? ☐ Yes ☐ No
8. Has patient been previously treated with Zolgensma? ☐ Yes ☐ No
9. Is Zolgensma prescribed concurrently with Spinraza? ☐ Yes ☐ No
10. Is patient currently on Spinraza? ☐ Yes ***Submit documentation & mark all that apply*** ☐ No
    - ☐ Evidence of clinical deterioration (e.g., sustained decrease in CHOP-INTEND score over a period of 3 to 6 months)
    - ☐ Provider attestation of clinical deterioration and Spinraza discontinuation
11. Does patient have an active viral infection (e.g., HIV, HBC, HCV, Zika, upper or lower respiratory tract infection)?
    ☐ Yes ***Mark all that apply*** ☐ No
    ☐ HIV ☐ Hepatitis B ☐ Hepatitis C ☐ Zika ☐ Upper/lower respiratory tract infection

Trillium Community Health Plan

Onasemnogene abeparvovec (Zolgensma)

Prior Authorization Form/Prescription

PLEASE COMPLETE ALL SECTIONS FOR A TIMELY REVIEW

Date: _____ Date Medication Required: _____
Ship to: ❍ Physician ❍ Patient's Home ❍ Other _____

☐ Non-respiratory tract infection ☐ Other: _____

Please continue to page 2.

Complete this section ONLY for indications <u>other</u> than spinal muscular atrophy:

12. Has patient tried and failed, or is contraindicated to, accepted standards of care? ☐ Yes ☐ No

If yes, submit documentation and answer the following:

a. Please list all previous therapies: _____

b. Was patient adherent to previously tried therapies? ☐ Yes ☐ No ☐ No, patient intolerant to drug

Physician's Signature _____ **Date:** _____ ☐ DAW

INFORMATION BELOW IS TO BE COMPLETE BY THE HEALTH PLAN/EPS PA STAFF

Authorization Information

Authorization number:	**Decision Due Date:**
J-Code:	**Coverage:** ❑ State excludes ❑ COB (secondary)
Line of Business: ❑ Commercial ❑ Health Insurance Marketplace ❑ Medicaid ❑ Medicare	**Benefit:** ❑ Medical ❑ Pharmacy

Criteria:

❑ Centene Policy

Date Policy last reviewed/approved by plan (we want to be sure we are using the version approved by your plan): _____

❑ State Specific (please include policy)

Medicare only criteria for CY2019 and CY2020:

❑ PART B use LCD or NCD ❑ PART D use MCPD.PA.247 Tier and Formulary Exceptions Request Criteria